Home › Compare › KLKBY vs ABBV
KLKBY yields 2.34% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, KLKBY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KLKBY + ABBV for your $10,000?
Kuala Lumpur Kepong Berhad engages in the plantation, manufacturing, and property development businesses. The company operates through Plantation, Manufacturing, Property Development, Investment Holding, and Others segments. It is involved in the cultivation, processing, and marketing of palm and rubber products; extraction of crude palm oil; refining of palm products; kernel crushing and trading of palm products; manufacturing and trading in oleochemicals, fatty acids, glycerin, industrial amides, fatty alcohol and methyl esters, non-ionic surfactants and esters, soap noodles, triacetin, special paper chemicals and surfactants, and palm phytonutrients and other palm derivatives; detergents, auxiliary materials for detergents and cosmetics, and basic organic chemicals from agricultural products; and alcohol ether sulphates, alcohol sulphates, and sulphonic acids. The company also provides rubber gloves, parquet flooring products, pharmaceutical and bio-pharmaceutical intermediates, and fine chemicals, as well as stores and distributes bulk liquid. In addition, it engages in farming and management services; and agronomic service and research, as well as operates biogas power plants; and develops residential and commercial properties. Further, the company operates holiday bungalows; manages properties; manufactures jams and preserves; and offers offshore captive insurance and logistics services related to palm products. It operates in Malaysia, Far East, the Middle East, South East Asia, Southern Asia, Europe, North America, South America, Australia, Africa, and internationally. The company was founded in 1906 and is based in Ipoh, Malaysia.
Full KLKBY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.